106 related articles for article (PubMed ID: 19856585)
1. Addressing bone loss in the cancer survivor.
O'Rourke ME; Ruble K
Oncology (Williston Park); 2009 Feb; 23(2 Suppl Nurse Ed):23-7. PubMed ID: 19856585
[No Abstract] [Full Text] [Related]
2. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
3. [Hepatic encephalopathy induced by flutamide administered for the treatment of prostatic cancer].
Patel H; Rhee E; Zimmern PE
J Urol (Paris); 1996; 102(3):123-5. PubMed ID: 9091557
[TBL] [Abstract][Full Text] [Related]
4. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition.
Smith MR; Goode M; Zietman AL; McGovern FJ; Lee H; Finkelstein JS
J Clin Oncol; 2004 Jul; 22(13):2546-53. PubMed ID: 15226323
[TBL] [Abstract][Full Text] [Related]
5. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Cherrier MM; Rose AL; Higano C
J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
[TBL] [Abstract][Full Text] [Related]
6. Interstitial pneumonitis related to leuprorelin acetate and flutamide.
Azuma T; Kurimoto S; Mikami K; Oshi M
J Urol; 1999 Jan; 161(1):221. PubMed ID: 10037405
[No Abstract] [Full Text] [Related]
7. Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide).
Isurugi K; Niijima T; Akaza H; Aso Y; Koiso K; Fuse M; Okada K; Usami M; Ohashi T; Ueda T;
J Chemother; 1989 Jul; 1(4 Suppl):1237-41. PubMed ID: 16312848
[No Abstract] [Full Text] [Related]
8. Testosterone suppression in men with prostate cancer is associated with increased arterial stiffness.
Dockery F; Bulpitt CJ; Agarwal S; Rajkumar C
Aging Male; 2002 Dec; 5(4):216-22. PubMed ID: 12630068
[TBL] [Abstract][Full Text] [Related]
9. Low bone mineral density in childhood acute lymphoblastic leukemia.
Naithani R; Desai A
Indian Pediatr; 2009 Jun; 46(6):542-3; author reply 543-4. PubMed ID: 19556673
[No Abstract] [Full Text] [Related]
10. Leuprolide with flutamide for complete androgen ablation: therapeutic alternative for advanced prostatic cancer (stage D2).
Chime-Udeh E
Conn Med; 1991 Sep; 55(9):526-8. PubMed ID: 1748007
[No Abstract] [Full Text] [Related]
11. Implantable LHRH agonist for treatment of prostate cancer.
Lajiness MJ
Urol Nurs; 2006 Oct; 26(5):408, 414. PubMed ID: 17078331
[No Abstract] [Full Text] [Related]
12. Bone loss accompanying medical therapies.
Dawson-Hughes B
N Engl J Med; 2001 Sep; 345(13):989-91. PubMed ID: 11575293
[No Abstract] [Full Text] [Related]
13. More should be done to prevent the harmful effects of long-term androgen ablation therapy in prostate cancer.
Barrass BJ; Thurairaja R; Persad RA
BJU Int; 2004 Jun; 93(9):1175-6. PubMed ID: 15180599
[No Abstract] [Full Text] [Related]
14. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression.
Higano C; Shields A; Wood N; Brown J; Tangen C
Urology; 2004 Dec; 64(6):1182-6. PubMed ID: 15596194
[TBL] [Abstract][Full Text] [Related]
15. Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Gardiner RA; Nicol DL; Green HJ; Yaxley J; Watson R; Mactaggart P; Headley BC; Swanson C; Pakenham KI
J Urol; 2004 Aug; 172(2):774; author reply 774-5. PubMed ID: 15247782
[No Abstract] [Full Text] [Related]
16. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
Malcolm JB; Derweesh IH; Kincade MC; DiBlasio CJ; Lamar KD; Wake RW; Patterson AL
Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
[TBL] [Abstract][Full Text] [Related]
17. What should I know about Lupron Depot for treating prostate cancer?
Johns Hopkins Med Lett Health After 50; 2012 Jan; 23(11):7. PubMed ID: 22396997
[No Abstract] [Full Text] [Related]
18. Localized amyloidosis of the seminal vesicle. Possible association with hormonally treated prostatic adenocarcinoma.
Unger PD; Wang Q; Gordon RE; Stock R; Stone N
Arch Pathol Lab Med; 1997 Dec; 121(12):1265-8. PubMed ID: 9431316
[TBL] [Abstract][Full Text] [Related]
19. Florid xanthomatous pelvic lymph node reaction to metastatic prostatic adenocarcinoma. A sequela of preoperative androgen deprivation therapy.
Schned AR; Gormley EA
Arch Pathol Lab Med; 1996 Jan; 120(1):96-100. PubMed ID: 8554456
[TBL] [Abstract][Full Text] [Related]
20. Histopathological effects of androgen deprivation in prostatic cancer.
Civantos F; Soloway MS; Pinto JE
Semin Urol Oncol; 1996 May; 14(2 Suppl 2):22-31. PubMed ID: 8725888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
